New Delhi, February 17: Deep-tech firm NeuroDx on Tuesday announced the development of Manas-1, a 400-million-parameter artificial intelligence brain language model designed to decode the electrical activity of the human brain.
The company said the breakthrough model is aimed at transforming diagnostics in neuroscience by enabling earlier detection of brain disorders and improving treatment accuracy.
Manas-1 Positioned to Advance AI-Based Brain Diagnostics
According to Siddharth Panwar, founder of NeuroDx.ai, Manas-1 has the potential to significantly enhance the way neurological conditions are identified and managed. By interpreting complex brain signals, the model is designed to assist in early-stage diagnosis and more precise clinical decision-making.Panwar said the company has submitted Manas-1 to the government for evaluation and validation under emerging standards for sovereign artificial intelligence assets. He noted that government approval would also be accompanied by funding support, which would accelerate further development of the platform.
Over 95 Percent Accuracy in Identifying Epilepsy Biomarkers
NeuroDx stated that, using Manas-1, it has achieved over 95 percent accuracy in identifying biomarkers associated with epilepsy and other mental health disorders. The company described this as a significant step toward building advanced AI-driven neurological diagnostic tools.Panwar added that Manas-1 is part of a broader research initiative to develop India’s first foundation-scale physiological state model. The larger objective is to create a system capable of interpreting human biosignals to generate advanced health and neurological insights.
Plans to Scale Model to 2 Billion Parameters
The company plans to expand the model’s capacity from 400 million parameters to 2 billion parameters in the coming months. This scale-up is expected to enhance the model’s analytical depth and diagnostic precision.“There are huge opportunities in the AI sector. Our product will meet the highest standards,” Panwar said, highlighting the firm’s ambitions in the rapidly evolving artificial intelligence landscape.
With Manas-1, NeuroDx is positioning itself at the intersection of AI innovation and neuroscience, aiming to strengthen India’s footprint in advanced health technology and sovereign AI development.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.